BioCryst Announces RAPIVAB Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting

By: via Benzinga
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced trial results related to RAPIVAB™ (peramivir injection), a ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.